GSK plc (GSK)
After hours:
| Previous close | 38.37 |
| Open | 38.07 |
| Bid | 38.40 x 2200 |
| Ask | 39.19 x 1100 |
| Day's range | 37.94 - 38.84 |
| 52-week range | 33.67 - 45.93 |
| Volume | |
| Avg. volume | 3,505,642 |
| Market cap | 79.173B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 12.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.53 (3.94%) |
| Ex-dividend date | 16 Aug 2024 |
| 1y target est | N/A |
- GlobeNewswire
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
--Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Latozinemab, a novel investigational human monoclonal antibody, is the most advanced PGRN-elevating candidate in development for the treatment of FTD-GRN-- SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
- Business Wire
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
PHILADELPHIA, September 18, 2024--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
- PR Newswire
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and older to embrace and protect the power they've found in aging by asking their doctor or pharmacist about their risk for shingles and about vaccination.
